Publicacións (321) Publicacións de CARLOS CAMPS HERRERO

2024

  1. Analysis of Diagnostic Delay and its Impact on Lung Cancer Survival: Results From the Spanish Thoracic Tumor Registry

    Archivos de Bronconeumologia, Vol. 60, pp. S38-S45

  2. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

    Lung Cancer, Vol. 194

  3. Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients

    Archivos de Bronconeumologia, Vol. 60, Núm. 2, pp. 88-94

  4. Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry

    Lung Cancer, Vol. 190

  5. Difficulties on the access to innovative targeted therapies for lung cancer in Spain

    Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 597-612

  6. Family history of cancer and lung cancer: Utility of big data and artificial intelligence for exploring the role of genetic risk

    Lung Cancer, Vol. 195

  7. KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination

    Cell Communication and Signaling, Vol. 22, Núm. 1

  8. Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial

    British Journal of Cancer, Vol. 130, Núm. 3, pp. 417-424

  9. QIM24-189: Molecular Tumor Boards Excellence. Phase 1-State of the Art in Spain

    Journal of the National Comprehensive Cancer Network : JNCCN, Vol. 22, Núm. 25

  10. Soluble galectin-3 as a microenvironment-relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma

    Molecular Oncology, Vol. 18, Núm. 1, pp. 190-215

  11. Whole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma

    eBioMedicine, Vol. 102

2023

  1. A Sonic Hedgehog Pathway Score to Predict the Outcome of Resected Non-Small Cell Lung Cancer Patients

    Annals of Surgical Oncology, Vol. 30, Núm. 2, pp. 1225-1235

  2. ASO Visual Abstract: A Sonic Hedgehog Pathway Score to Predict the Outcome of Resected Non-small Cell Lung Cancer Patients

    Annals of surgical oncology, Vol. 30, Núm. 2, pp. 1238-1239

  3. Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study

    ERJ Open Research, Vol. 9, Núm. 6

  4. Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer

    Thrombosis Research, Vol. 232, pp. 133-137

  5. Circulating Immune Proteins: Improving the Diagnosis and Clinical Outcome in Advanced Non-Small Cell Lung Cancer

    International Journal of Molecular Sciences, Vol. 24, Núm. 24

  6. Clinical and technical insights of tumour mutational burden in non-small cell lung cancer

    Critical Reviews in Oncology/Hematology, Vol. 182

  7. Machine Learning Survival Models for Relapse Prediction in a Early Stage Lung Cancer Patient

    Proceedings of the International Joint Conference on Neural Networks

  8. Machine Learning-Assisted Recurrence Prediction for Patients With Early-Stage Non-Small-Cell Lung Cancer

    JCO clinical cancer informatics, Vol. 7, pp. e2200062

  9. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer

    New England Journal of Medicine, Vol. 389, Núm. 6, pp. 504-513